Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | January 02, 2025 | January 06, 2025 |
| Longeveron Inc.LGVN · Entity 7608 | Director | July 15, 2025 | July 17, 2025 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Director | June 20, 2024 | June 21, 2024 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director · See Remarks | July 08, 2026 | July 10, 2026 |
| Syneos Health, Inc.INCR · Entity 109360 | Director | May 23, 2017 | May 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 23,000 |
Reported balance
After 2025-01-02 transaction · row 1
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 6,250 · Balance 23,000 F1: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2: Each RSU represents a contingent right to receive one ordinary share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-01-02 | Direct | 12,500 |
Reported balance
After 2025-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-02 · Grant · Acquired 12,500 · Balance 12,500 F3: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025.
Longeveron Inc.
Report date July 15, 2025 · Filed July 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 33,000 |
Reported balance
After 2025-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-15 · Grant · Acquired 17,000 · Balance 33,000 F1: Represents the award of time-based vesting Restricted Stock Units (RSUs). F2: Includes RSUs subject to future vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of time-based vesting Restricted Stock Units (RSUs).
F2: Includes RSUs subject to future vesting.
Omega Therapeutics, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2034-06-19 | Direct | 50,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests and becomes exercisable in thirty-six substantially equal monthly installments following the date of grant, such that the option shall be fully vested and exercisable on the third anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in thirty-six substantially equal monthly installments following the date of grant, such that the option shall be fully vested and exercisable on the third anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such vesting date.
Seres Therapeutics, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-03-03 | Direct | 50,000 |
Reported balance
After 2026-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests and becomes exercisable in 36 equal monthly installments following the March 2, 2026 vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in 36 equal monthly installments following the March 2, 2026 vesting commencement date.
Syneos Health, Inc.
Report date May 23, 2017 · Filed May 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 7,148 |
Reported balance
After 2017-05-23 transaction · row 1
1 source rowRow 1 · 2017-05-23 · Grant · Acquired 2,693 · Balance 7,148 F1: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 16:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001193125-26-300925 · ownership.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-03-03 F1 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments following the March 2, 2026 vesting commencement date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 16:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001193125-26-096711 · ownership.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-03-03 F1 · derivative.exercise_date: The option vests and become exercisable in 36 equal monthly installments. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 19:44 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantClass A Common Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-010568 · marketforms-70113.xml · nonDerivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 F1 · shares: Represents the award of time-based vesting Restricted Stock Units (RSUs). F2 · balance_after: Includes RSUs subject to future vesting. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000950170-25-053246 · ownership.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option vests in full on the earlier of April 10, 2026 or the day immediately prior to the company's 2026 annual meeting of shareholders. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000918 · form4-01062025_070106.xml · derivative · entry 2 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Ordinary Shares · 12,500 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000918 · form4-01062025_070106.xml · nonDerivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 16:20 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0000950170-24-076260 · ownership.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The option vests and becomes exercisable in thirty-six substantially equal monthly installments following the date of grant, such that the option shall be fully vested and exercisable on the third anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such vesting date. Read SEC document |
| May 10, 2024 Filed May 14, 2024 19:10 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantClass A Common Stock | 16,000 | $1.46 | $23,280.00 |
DisclosureSEC source: 0001214659-24-009103 · marketforms-65873.xml · nonDerivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Grant of restricted stock units, which vest quarterly in equal installments over a period of three years, under the Company's Equity Incentive Plan. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 16:45 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0000950170-24-042651 · ownership.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-04-03 F1 · derivative.exercise_date: The option vests in full on the earlier of April 4, 2025 or the day immediately prior to the company's 2025 annual meeting of shareholders. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 18:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $18.08 | $0.00 |
DisclosureSEC source: 0001209191-24-000881 · doc4.xml · derivative · entry 2 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires 2034-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 18:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000881 · doc4.xml · nonDerivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,750 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 17:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0000899243-23-016396 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2024 or the day immediately prior to the company's 2024 annual meeting of shareholders. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:08 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-23-002183 · doc4.xml · derivative · entry 2 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Ordinary Shares · 11,500 shares Expires 2033-01-03 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2023, June 15, 2023, September 15, 2023 and December 15, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:08 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002183 · doc4.xml · nonDerivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,750 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2023, June 15, 2023, September 15, 2023 and December 15, 2023. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 19:23 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantCOMMON STOCK | 63,492 | $3.15 | $199,999.80 |
DisclosureSEC source: 0000899243-22-025515 · doc4.xml · nonDerivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,492 Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 16:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000899243-22-024013 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 16:32 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000899243-22-023990 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:22 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $60.87 | $0.00 |
DisclosureSEC source: 0001209191-22-001817 · doc4.xml · derivative · entry 2 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:22 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001817 · doc4.xml · nonDerivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs are fully vested. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 16:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $19.74 | $0.00 |
DisclosureSEC source: 0000899243-21-024990 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The option vests in full on the earlier of June 16, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 17:39 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001209191-21-001388 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Ordinary Shares · 19,000 shares Expires 2031-01-04 Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 16:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0000899243-20-017354 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 8,202 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-20-002011 · doc4.xml · derivative · entry 2 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,202 Underlying: Ordinary Shares · 8,202 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following July 18, 2019. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-20-002011 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Ordinary Shares · 16,000 shares Expires 2030-01-02 Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 16:38 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (Right to Buy) · Derivative | 23,798 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-19-051101 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,798 Underlying: Ordinary Shares · 23,798 shares Expires 2029-09-26 F1 · derivative.exercise_date: The shares underlying this option shall vest in 36 equal monthly installments commencing on July 18, 2019. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 16:10 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000899243-19-017013 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 21:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000899243-18-018521 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-25 F1 · derivative.exercise_date: The option vests in full on the earlier of June 26, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 17:19 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.21 | $0.00 |
DisclosureSEC source: 0000899243-17-016865 · doc4.xml · derivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 16:10 UTC | Syneos Health, Inc. INCR · Entity 109360 | GrantClass A Common Stock | 2,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001610950-17-000030 · wf-form4_149565659238834.xml · nonDerivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,148 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.